'Arcus Biosciences Set to Join S&P SmallCap 600,' Replacing Investors Bancorp -S&P Dow Jones Indices
$CFG
$ISBC
$RCUS
Major Banks
Finance
Savings Institutions
Finance
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/21/2024 | $20.00 | Neutral | H.C. Wainwright | |
| 10/8/2024 | $29.00 | Overweight | Wells Fargo | |
| 7/11/2024 | Mkt Perform | Raymond James | ||
| 4/26/2024 | $35.00 → $41.00 | Neutral → Overweight | Piper Sandler | |
| 2/5/2024 | $36.00 | Neutral → Buy | Citigroup | |
| 1/2/2024 | $38.00 → $40.00 | Overweight → Equal Weight | Barclays | |
| 12/4/2023 | $31.00 | Overweight → Equal-Weight | Morgan Stanley | |
| 10/25/2023 | $29.00 → $26.00 | Overweight → Neutral | Piper Sandler |
New Heads of Mortgage, Consumer Lending and Retail Banking bring deep experience to accelerate ongoing transformation and meet customers' evolving needs Citizens is pleased to announce the appointment of three key executives to accelerate the bank's ongoing transformation and commitment to deliver the best experience for customers. Raman Muralidharan has been appointed as the Head of Mortgage, and two accomplished senior executives have been promoted: Adam Boyd to Head of Lending and Nuno Dos Santos to Head of Retail Banking. These leadership appointments will bolster Citizens' growth plans while enhancing its relationship-based banking model. "The appointment of three highly experience
Citizens Financial Group, Inc. (NYSE:CFG) today announced the appointment of Claude E. Wade to the company's Board of Directors, effective March 1, 2025. Wade's appointment will temporarily expand the Citizens Board to 14 directors. He will serve on the Board's Risk Committee. Wade, who has over 30 years of operational, strategy and innovation roles, primarily with Fortune 100 companies, serves as executive vice president, Chief Digital Officer and Global Head of Business Operations and Global Head of Claims at AIG, overseeing its business operations, claims, data, innovation and digital teams. Prior to joining AIG in 2021, he served as BlackRock's Global Head of Client Experience and Head
Today, Citizens Financial Group (NYSE:CFG) announced that it has appointed Christopher Schnirel as Controller and Chief Accounting Officer, effective October 21, 2024. "We are pleased to welcome Chris to Citizens, where he will play a key role in maintaining a high standard of excellence in financial reporting and controls as well as supporting our strategic agenda," said John Woods, Vice Chair and Chief Financial Officer. "He brings great expertise and over 20 years of strong leadership experience in financial services." Schnirel, most recently was the Senior Vice President and Assistant Controller at Huntington Bancshares Inc., where he led SEC reporting, regulatory reporting, accountin
13F-HR - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Filer)
10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
SC 13G - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Subject)
SC 13G/A - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
4 - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Issuer)
4 - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Issuer)
4 - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Issuer)
H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00
Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00
Raymond James initiated coverage of Citizens Financial Group with a rating of Mkt Perform
Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the randomized ARC-
Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36% reduction in risk of death (HR=0.64) was observed for domvanalimab plus zimberelimab compared to zimberelimab alone; zimberelimab reached a median overall survival of two years while the median overall survival for domvanalimab plus zimberelimab was not reached Treatment-related adverse events leading to treatment discontinuation were low (10.5%) for the combination of domvanalimab and zimberelimab relative to chemotherapy (23.5%) Arcus will discuss these results on its earnings call at 2:00 PM
Citizens Financial Group, Inc. (NYSE:CFG) announced that its board of directors has declared the following dividends on its preferred stock payable on January 6, 2025, to preferred shareholders of record at the close of business on December 20, 2024: a quarterly cash dividend of $19.85400083 per share on CFG's 6.000% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series B (CUSIP No. 174610AP0); a quarterly cash dividend of $20.24327861 per share on CFG's 6.375% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series C (CUSIP No. 174610AQ8); a quarterly cash dividend of $12.50 per share ($0.3125 per each depositary share, each representing a 1/40th int
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7th Annual HealthCONx Conference Date: Tuesday, December 3rd, 2024 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 7:55 a.m. ET Citi 2024 Global Healthcare Conference Date: Wednesday, December 4th, 2024 Location: Miami, FL Format: 1x1 meetings only Live webcasts of the fireside chats and panel will be available by visiting the "Investors & Media" section of the Arcus
New Heads of Mortgage, Consumer Lending and Retail Banking bring deep experience to accelerate ongoing transformation and meet customers' evolving needs Citizens is pleased to announce the appointment of three key executives to accelerate the bank's ongoing transformation and commitment to deliver the best experience for customers. Raman Muralidharan has been appointed as the Head of Mortgage, and two accomplished senior executives have been promoted: Adam Boyd to Head of Lending and Nuno Dos Santos to Head of Retail Banking. These leadership appointments will bolster Citizens' growth plans while enhancing its relationship-based banking model. "The appointment of three highly experience
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company's common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and restricted stock units to acquire a total of 7,050 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January
Citizens Financial Group's (NYSE:CFG) short percent of float has risen 29.78% since its last report. The company recently reported that it has 12.01 million shares sold short, which is 3.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.51 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Sho
In the latest quarter, 13 analysts provided ratings for Citizens Financial Group (NYSE:CFG), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 6 0 0 Last 30D 0 1 0 0 0 1M Ago 3 1 4 0 0 2M Ago 0 0 1 0 0 3M Ago 1 1 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $41.31, along with a high estimate of $49.00 a
Stephens & Co. analyst Terry McEvoy maintains Citizens Financial Group (NYSE:CFG) with a Overweight and raises the price target from $40 to $42.
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Issuer)